You can enroll as a voter for MLC elections now if you have not enrolled earlier.
https://ceotserms1.telangana.gov.in/MLC/Form18.aspx
, ?|| Astrazeneca- Sputnik combination vaccine ||
AstraZeneca, the British drugmaker working with the University of Oxford to develop a COVID-19 vaccine, plans to work with the developers of Russia's Sputnik V to explore a combined shot, it said.
AstraZeneca "will soon begin exploring with Gamaleya Research Institute in Russia to understand whether two adenovirus-based vaccines can be successfully combined," the drugmaker said in a statement Friday, naming the developer of the Sputnik V vaccine, but not the specific shot.
The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, confirmed the vaccine in question was one of two vectors that make up Sputnik V.
Clinical trials are slated to begin by the end of December, the RDIF, which is financing the development of Sputnik V, added.
This is the second time AstraZeneca's vaccine is being used in a "mix and match" trial. On Tuesday, the head of the UK's vaccine taskforce said it would combine the shot with Pfizer's vaccine to see if the two vaccines together produce a stronger immune response.
Combining different COVID-19 vaccines "may be helpful to improved protection and/or to improve vaccine accessibility," AstraZeneca said Friday, adding that it "is also likely that combining vaccines may lead to improved immunity over a longer-period of time."
About SocialNewsXYZ
An Indo-American News website. It covers Gossips, Politics, Movies, Technolgy, and Sports News and Photo Galleries and Live Coverage of Events via Youtube. The website is established in 2015 and is owned by AGK FIRE INC.
You can enroll as a voter for MLC elections now if you have not enrolled earlier. https://ceotserms1.telangana.gov.in/MLC/Form18.aspx , ?|| Astrazeneca- Sputnik combination vaccine || AstraZeneca, the British drugmaker working with the University of Oxford to develop a COVID-19 vaccine, plans to work with the developers of Russia's Sputnik V to explore a combined shot, it said. AstraZeneca "will soon begin exploring with Gamaleya Research Institute in Russia to understand whether two adenovirus-based vaccines can be successfully combined," the drugmaker said in a statement Friday, naming the developer of the Sputnik V vaccine, but not the specific shot. The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, confirmed the vaccine in question was one of two vectors that make up Sputnik V. Clinical trials are slated to begin by the end of December, the RDIF, which is financing the development of Sputnik V, added. This is the second time AstraZeneca's vaccine is being used in a "mix and match" trial. On Tuesday, the head of the UK's vaccine taskforce said it would combine the shot with Pfizer's vaccine to see if the two vaccines together produce a stronger immune response. Combining different COVID-19 vaccines "may be helpful to improved protection and/or to improve vaccine accessibility," AstraZeneca said Friday, adding that it "is also likely that combining vaccines may lead to improved immunity over a longer-period of time."